Literature DB >> 18673171

Medicinal chemistry of Hsp90 inhibitors.

Martin J Drysdale1, Paul A Brough.   

Abstract

Heat shock protein (Hsp90) inhibitors are an increasingly interesting and important class of compounds where the first in class, natural product derived inhibitors such as 17-allylaminogeldanamycin (17-AAG), are entering late stage clinical development. Recently the emergence of synthetic, small molecule inhibitors has been described and both NVP-AUY922 and BIIB021 have entered clinical development. The medicinal chemistry of these and other published small molecule Hsp90 inhibitors is described in this review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673171     DOI: 10.2174/156802608784911644

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

2.  Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.

Authors:  Byoung Heon Kang; Markus D Siegelin; Janet Plescia; Christopher M Raskett; David S Garlick; Takehiko Dohi; Jane B Lian; Gary S Stein; Lucia R Languino; Dario C Altieri
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

3.  A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.

Authors:  Ying Yang; Huanxiang Liu; Juan Du; Jin Qin; Xiaojun Yao
Journal:  J Mol Model       Date:  2011-03-04       Impact factor: 1.810

4.  Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis.

Authors:  Amy L Strayer; Cassandra N Dennys-Rivers; Karina C Ricart; Narae Bae; Joseph S Beckman; Maria Clara Franco; Alvaro G Estevez
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-29

Review 5.  The role of ligand efficiency metrics in drug discovery.

Authors:  Andrew L Hopkins; György M Keserü; Paul D Leeson; David C Rees; Charles H Reynolds
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 6.  Protein chaperones: a composition of matter review (2008 - 2013).

Authors:  Tony Taldone; Hardik J Patel; Alexander Bolaender; Maulik R Patel; Gabriela Chiosis
Journal:  Expert Opin Ther Pat       Date:  2014-05       Impact factor: 6.674

7.  Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.

Authors:  B H Kang; M Tavecchio; H L Goel; C-C Hsieh; D S Garlick; C M Raskett; J B Lian; G S Stein; L R Languino; D C Altieri
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

Review 8.  NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes.

Authors:  David M Dias; Alessio Ciulli
Journal:  Prog Biophys Mol Biol       Date:  2014-08-28       Impact factor: 3.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.